Previously, we reported that levels of
chymase activity and its
mRNA in cardiac tissues were significantly increased along with progression of cardiac
fibrosis in cardiomyopathic hamsters, but the involvement of
chymase in the progression of
fibrosis has been unclear. In cultured human fibroblasts, the concentration of
transforming growth factor-beta in the supernatant of medium was significantly increased after injection of human
chymase. Furthermore, human
chymase dose dependently increased cell proliferation, and this
chymase-dependent proliferation was completely suppressed by a
chymase inhibitor, Suc-Val-Pro-Phe(p)(OPh)(2) (10 micro M) or an anti-
transforming growth factor-beta antibody (100 micro g/ml). In this study, we used Bio14.6 and F1B hamsters as cardiomyopathic and control hamsters, respectively. Cardiomyopathic hamsters were orally administered a novel
chymase inhibitor, 4-[1-([bis-(4-methylphenyl)-methyl]-carbamoyl)-3-(2-ethoxy-benzyl)-4-oxo-
azetidine-2-yloxy]-
benzoic acid (BCEAB; 100 mg/kg per day), or placebo from 5- to 45-week-old. In the placebo-treated group, the cardiac
chymase activity in cardiomyopathic hamsters 45 weeks old was significantly increased compared with that in control hamsters. BCEAB significantly reduced the cardiac
chymase activity. The indexes (+dP/dt and -dP/dt) of cardiac function were significantly improved by treatment with BCEAB. The
mRNA levels of
collagen I and
collagen III in the placebo-treated hamsters were significantly reduced to 69.6 and 76.5% by treatment with BCEAB, respectively. The fibrotic area in cardiac tissues in the BCEAB-treated hamsters was significantly suppressed to 50.7% compared with that in the placebo-treated treated hamsters. Therefore, the activation of
transforming growth factor-beta by
chymase may play an important role in the progression of cardiac
fibrosis and cardiac dysfunction in
cardiomyopathy.